434 related articles for article (PubMed ID: 33215284)
1. BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease.
Fischer DL; Auinger P; Goudreau JL; Cole-Strauss A; Kieburtz K; Elm JJ; Hacker ML; Charles PD; Lipton JW; Pickut BA; Sortwell CE
Neurotherapeutics; 2020 Oct; 17(4):1785-1795. PubMed ID: 33215284
[TBL] [Abstract][Full Text] [Related]
2. BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease.
Sortwell CE; Hacker ML; Fischer DL; Konrad PE; Davis TL; Neimat JS; Wang L; Song Y; Mattingly ZR; Cole-Strauss A; Lipton JW; Charles PD
Neuromodulation; 2022 Aug; 25(6):846-853. PubMed ID: 34288271
[TBL] [Abstract][Full Text] [Related]
3. Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.
Fischer DL; Auinger P; Goudreau JL; Paumier KL; Cole-Strauss A; Kemp CJ; Lipton JW; Sortwell CE
Parkinsonism Relat Disord; 2018 Aug; 53():70-75. PubMed ID: 29759928
[TBL] [Abstract][Full Text] [Related]
4.
Fischer DL; Auinger P; Goudreau JL; Paumier KL; Cole-Strauss A; Kemp CJ; Lipton JW; Sortwell CE
Front Neurol; 2022; 13():1053591. PubMed ID: 36468063
[TBL] [Abstract][Full Text] [Related]
5. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
[TBL] [Abstract][Full Text] [Related]
6. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
[TBL] [Abstract][Full Text] [Related]
7. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
8. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Fahn S;
J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the role of brain derived neurotrophic factor genetic variation in Alzheimer's disease neurodegeneration.
Honea RA; Cruchaga C; Perea RD; Saykin AJ; Burns JM; Weinberger DR; Goate AM;
PLoS One; 2013; 8(9):e76001. PubMed ID: 24086677
[TBL] [Abstract][Full Text] [Related]
10. Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease.
Mueller K; Jech R; Růžička F; Holiga Š; Ballarini T; Bezdicek O; Möller HE; Vymazal J; Růžička E; Schroeter ML; Urgošík D
Neuroimage Clin; 2018; 19():1025-1035. PubMed ID: 30035027
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of deep brain stimulation in severe Parkinson's disease utilizing UPDRS III and modified Hoehn and Yahr as a severity scale.
Kahn L; Mathkour M; Lee SX; Gouveia EE; Hanna JA; Garces J; Scullen T; McCormack E; Riffle J; Glynn R; Houghton D; Lea G; Biro EE; Bui CJ; Sulaiman OA; Smith RD
Clin Neurol Neurosurg; 2019 Apr; 179():67-73. PubMed ID: 30851616
[TBL] [Abstract][Full Text] [Related]
13. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
14. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
15. The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
Mercado NM; Stancati JA; Sortwell CE; Mueller RL; Boezwinkle SA; Duffy MF; Fischer DL; Sandoval IM; Manfredsson FP; Collier TJ; Steece-Collier K
Neurobiol Dis; 2021 Jan; 148():105175. PubMed ID: 33188920
[TBL] [Abstract][Full Text] [Related]
16. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
17. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Hoy SM; Keating GM
Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
[TBL] [Abstract][Full Text] [Related]
18. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
19.
Sun HM; Wang LN; Ji M; Gan CT; Yuan YS; Cao XY; Zhang H; Zhang KZ
Quant Imaging Med Surg; 2022 Jun; 12(6):3264-3275. PubMed ID: 35655818
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Awake vs. Asleep Surgery for Subthalamic Deep Brain Stimulation in Parkinson's Disease.
Blasberg F; Wojtecki L; Elben S; Slotty PJ; Vesper J; Schnitzler A; Groiss SJ
Neuromodulation; 2018 Aug; 21(6):541-547. PubMed ID: 29532560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
